VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
Vertex Pharmaceuticals Inc VRTX shares are rising in extended trading Monday after the company announced positive interim results for one of its Phase 3 trials. Vertex Pharmaceuticals stock is trading ...
Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wagner announced, "We now expect 2025 total revenue to be in a range of $11.9 billion to $12 billion versus prior guidance of $11.85 billion to $12 billion, representing growth of approximately 8% to ...
The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.
Wagner guided, "We expect full year 2026 total company revenue to be in the range of $12.95 billion to $13.1 billion, representing 8% to 9% growth versus the prior year. This outlook anticipates ...
Investing.com -- Vertex Pharmaceuticals (NASDAQ:VRTX) shares rose 6% to $488.52 in premarket trading Thursday after the company reported successful results from a late-stage trial of its kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results